Handling Ovarian Cancer FIGO III-IV: Evolution over the last 30 years

References

• Tothill R. W., TinkerA. V., George J. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res, 2008, 14(16): 5198–5208.
   Google Scholar
• Kurman R. J., Ie-Ming Shih. Pathogenesis of ovarian cancer: Lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol, 2008, 27(2): 151–160.
   Google Scholar
• Aure J. c., Hoeg K., Kolstad P. clinical and histologic studies of ovarian carcinoma. Long term follow-up of 990 cases. Obstet Gynecol, 1971, 37: 1–14.
   Google Scholar
• Young R. c., chabner B. A., Hubbard S. P. et al. Advanced ovarian adenocarcinoma: a prospective clinical trial of Melphalan (L PAm) vs combination chemotherapy. N Eng J Med, 1978, 299: 1262–1266.
   Google Scholar
• Ehrlich c. E., Einhorn L., Williams S. D. et al. chemotherapy for stage III-IV epithelial ovarian cancer with cisplatin, adriamycin and cyclophosphamide: a prelimary report. Cancer Treat Rep, 1979, 63: 281–288.
   Google Scholar
• Bagley c. M., Young R. c., canellos G. P., De Vita V. T. Treatment of ovarian carcinoma: possibilities for progress. N Eng J Med, 1972, 287(17): 856–862.
   Google Scholar
• Smith J. P, Day T. G. A review of ovarian cancer at the University of Texas Systems cancer center, M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol, 1979, 135: 984–990.
   Google Scholar
• Griffiths c. T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr, 1975, 42: 101–4.
   Google Scholar
• Griffiths c. T, Fuller A. F. Intensive surgical and chemothera-peutic management of advanced ovarian cancer. Surg Clin N Am, 1978, 58: 131–142.
   Google Scholar
• Moore G. E. Debunking debulking. Surg Gynecol Obstet, 1980, 150: 395–396.
   Google Scholar
• De Wever I. Surgery for advanced ovarian cancer. A critical analysis of its contribution to combined treatment. PhD thesis, catholic university Leuven, 1991.
   Google Scholar
• conte P. F., AlanaA., Rubagotti A. et al. cell kinetics in ovarian cancer. Cancer, 1989, 64: 1188–1191.
   Google Scholar
• Vergote I., De Wever I., Tjalua W. et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma. A retrospective analysis of 285 patients. Gynecol Oncol, 1998, 71:431–436.
   Google Scholar
• Winter Ill W. E., Maxwell G. L., Tian c. et al. Prognostic factors for stage Ill epithelial ovarian cancer: A gynecologic oncology group study. J Clin Oncol, 2007, 25: 3621–3627.
   Google Scholar
• Teramukai S., Ochiai K., Tada H., Fukushima M. PIEPOC: A new prognostic index for advanced epithelial ovarian cancer-Japan multinational trial organization Oc01–01. J Clin Oncol, 2007, 25: 3302–3306.
   Google Scholar
• Bristow R. E., Tomacruz R. S., Armstrong D. K., Trimble El., Müntz F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinium era: metaanalysis. J Clin Oncology, 2002, 20: 1248–59.
   Google Scholar
• Fader A. N, Rose P. G. Role of surgery in ovarian carcinoma. J Clin Oncol, 2007, 25 (20): 2873–2883.
   Google Scholar
• Covens A. L. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecologic Oncology, 2000, 78: 269–274.
   Google Scholar
• Crawford S. C., Vasey P. A., Paul J., Hay A., Davis J. A., Kaye S. B. Does aggressive surgery only benefit patients with less advanced ovarian cancer ? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol, 2005, 23: 88028811.
   Google Scholar
• Van der Burg M. E., Van Lent M., Buyse M. et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Ned, 1995, 332: 629–34.
   Google Scholar
• Bristow R. E., EisenhauerE. L., Santillana., ChiD. S. Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecologic Oncology 2007, 104: 480–490.
   Google Scholar
• Vergüte I., Van Gorp T., Amant F., Leunen K., Neven P, Berteloot P. Timing of debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer, 2008, 18 (suppl. 1): 11–19.
   Google Scholar
• Rose P. G., Nerenstone S., Brady M. F., Clarke-Pearson D., Olt G., Rubin S. C. et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med, 2004, 351: 2489–97.
   Google Scholar
• Fagotti A., Ferrnandina G., Fanfani F. et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol, 2008, 199: 642.e1–642.e6.
   Google Scholar
• Risum S., H0gdall A., Loft A. et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography A prospective study. Gynecologic Oncology, 2008, 108: 265–270.
   Google Scholar
• Chi D. S, Zivanovic O., Palayekar M. J. et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal an peritoneal carcinoma. Gynecologic Oncology, 2009, 112: 6–10.
   Google Scholar
• Salani R., Axtell A., Gerardi M., Hoschneider C., Bristow R. E. Limited utility of conventional criteria for predicting disease in patients with advanced stage epithelial ovarian cancer. Gynecologic Oncology, 2002, 108: 271–275.
   Google Scholar
• Eisenhauer E. L., Abu-Rustum N. R., Sonoda Y., Aghajanian C., Barakat R. R., Chi D. S. The effect of maximal surgical cytore-duction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecologic Oncology, 2008, 108: 276–281.
   Google Scholar
• Markman M. Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action. J Clin Oncol, 2007, 25(27): 4168–4170.
   Google Scholar
• Aletti G. D., Dowdy S. C., Podratz K. C., William A., Cliby A. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol, 2007, 197: 676.e1–676.e7.
   Google Scholar
• Zivanovic O., Eisenhauer E. L., Zhou Q. et al. The impact on bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage iiic epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic Oncology, 2008, 108: 287–292.
   Google Scholar
• Chan J. K., Urban R., Hu J. M. et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer, 2007, 96: 1817–1822.
   Google Scholar
• Benedetti Panici P., Maggiani A., Hacker N. et al. Systemic aortic and pelvic lymphadenectomy vs resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst, 2005, 97: 560–566.
   Google Scholar
• Angioli R., Plotti F., Palaia I. et al. Update on lymphadenectomy in early advanced ovarian cancer. Curr Opin Obstet Gynecol, 2008, 20: 34–39.
   Google Scholar
• Hacker NF., Valmadre S., Robertson G. Management of retroperitoneal lymph nodes in advanced ovarian cancer. Int J Gynecol Cancer, 2008, 18 (suppl. 1): 7–10.
   Google Scholar